An analysis of the Duffy Antigen Receptor for Chemokines/Atypical Chemokine Receptor 1 (DARC/ACKR1) and Risk of Triple Negative Breast Cancer (TNBC)

Georgia's Online Cancer Information Center

Find A Clinical Trial

An analysis of the Duffy Antigen Receptor for Chemokines/Atypical Chemokine Receptor 1 (DARC/ACKR1) and Risk of Triple Negative Breast Cancer (TNBC)

Status
Active
Cancer Type
Breast Cancer
Trial Phase
Eligibility
Females over the age of 18, Female
Study Type
Other
NCT ID
Protocol IDs
DARC (primary)
Study Sponsor
Morehouse School of Medicine
NCI Full Details

Summary

Despite a recent convergence of breast cancer (BC) incidence rates between African American (AA) and European American (EA) women, AA women continue to have ~40% higher mortality rates. BC is a heterogeneous collection of diseases, where African ancestry women are disproportionately burdened with the most aggressive subtype of BC, triple negative BC (TNBC). We have previously reported that the African ancestry-specific Duffy-null allele (FY-) is a risk factor for TNBC diagnoses. FY- is a promoter variant that removes expression of the Duffy Antigen Receptor for Chemokines (DARC/ACKR1), from red blood cells (RBCs). DARC serves as a portal of entry for Plasmodium vivax malaria parasite, and FY- confers immunity, leading to fixation of FY- among Sub-Saharan African populations. DARC is an atypical chemokine receptor that functions to modulate chemokine levels in circulation and tissues to aid immune cell recruitment. DARC is also expressed on breast tumor epithelial cells, however the significance of DARC in the TNBC tumor microenvironment (TME) has not fully been explored. Leveraging our African ancestry enriched International Study for the Center of Breast Cancer Subtypes cohort and in vivo murine models, we employed multi-omics approaches to explore the function of FY- and DARC expression across cell types in the TNBC TME.
 
For more infromation, click here
 
 
Abstract: https://aacrjournals.org/cancerres/article/84/9_Supplement/PS18-09/744440/Abstract-PS18-09-The-DARC-side-of-Breast-Cancer

Objectives

  • To document DARC/ACKR1 genotype variants in breast cancer patients with diverse heritage (characterized by self-report as well as germline/genetic ancestry)
    • White Americans/European ancestry
    • African Americans
    • Asians Americans
  • To correlate genotypes of DARC/ACKR1 with breast tumor phenotypes and tumor immune cell infiltration
    • Triple negative breast cancer vs. non-triple negative breast cancer
  • To correlate population-specific genotypes of DARC/ACKR1 with circulating chemokine levels
    • CCL2
    • CXCL8
    • CCL11
  • To correlate population-specific genotypes of DARC/ACKR1 with somatic/tumor expression of DARC/ACKR1 protein and tumor immune cell infiltration
  • To correlate chemokine levels and somatic/tumor expression of DARC/ACKR1 protein with breast tumor phenotypes and tumor immune cell infiltration
    • Triple negative breast cancer vs. non-triple negative breast cancer

Eligibility

  • Inclusion Criteria
    • Females over the age of 18
    • Females that either have
      • A new invasive (Stage 11-V) breast cancer diagnosis
        • OR
      • Have no cancer diagnosis (healthy controls)
  • Exclusion Criteria
    • Females with a previous diagnosis other than breast cancer
    • Females with a non-invasive breast cancer diagnosis

Treatment Sites in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.